Comments
Loading...

Estrella Immunopharma Earnings Estimates

ESLANASDAQ
Logo brought to you by Benzinga Data
$1.81
0.084.62%
At close: Dec 15, 4:00 PM EST
$2.12
0.3117.13%
After Hours: Dec 10, 6:56 AM EST

Estrella Immunopharma Earnings Estimates, EPS & Revenue | NASDAQ:ESLA | Benzinga

Estrella Immunopharma reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.

Earnings Date
Nov 12
EPS
$-0.130
Quarterly Revenue
$0.00
Annual Revenue
(as of Sep 30)

Analyze the earnings history of Estrella Immunopharma using advanced sorting and filters.

Get Alert
ESLAEstrella Immunopharma-$0.13$0.0002/26/2026Get Alert
ESLAEstrella Immunopharma-$0.01-$0.13$0.00$0.0011/12/2025Get Alert
ESLAEstrella Immunopharma-$0.11-$0.11-$0.15-36.36%$0.00$0.0008/12/2025Get Alert
ESLAEstrella Immunopharma-$0.03-$0.06$0.00$0.0005/14/2025Get Alert
ESLAEstrella Immunopharma-$0.13$0.0009/27/2024Get Alert
ESLAEstrella Immunopharma-$0.01$0.0005/15/2024Get Alert
ESLAEstrella Immunopharma-$0.03$0.0002/14/2024Get Alert

Estrella Immunopharma (ESLA) Earnings Per Share

Quarterly Earnings Surprise Amount

Fiscal QuarterDate ReportedActual EPSEstimated EPSSurprise %
Q22025-08-12$-0.15$-0.11-36.4 %

Estrella Immunopharma (ESLA) Revenue

Quarterly Revenue Surprise Amount

Fiscal QuarterDate ReportedActual RevenueEstimated RevenueSurprise %

FAQ

Q

When is Estrella Immunopharma (NASDAQ:ESLA) reporting earnings?

A

Estrella Immunopharma (ESLA) is scheduled to report earnings on February 26, 2026. The last reported earnings were for reported on November 12, 2025 for Q3.

Q

What were the latest earnings per share (EPS) for Estrella Immunopharma (NASDAQ:ESLA)?

A

The Actual EPS was $-0.13, which missed the estimate of $0.00.

Q

What were Estrella Immunopharma’s (NASDAQ:ESLA) revenues?

A

The Actual Revenue was $0K, which hit the estimate of $0K.

Browse earnings estimates, EPS, and revenue on all stocks.